Phosphofructokinase Deficiency Glycogen Storage Disease

carol17830 Barbara3 chenoa 104 Users are discussing this topic

oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

Synonyms: Tarui's disease, glycogen storage disease type VII, muscle phosphofructokinase deficiency

Phosphofructokinase (PFK) deficiency is a glycogen storage disorder (GSD). It is rare and is inherited as an autosomal recessive disorder. There is a mutation in the gene encoding muscle PFK on chromosome 12.[1] There is also reduced activity of red cell PFK. The main clinical features include exercise intolerance, muscle cramping, exertional myopathy, compensated haemolysis and myoglobinuria.[1] There are three subtypes:

  • Infantile-onset (a few rare cases have been reported).
  • Classic (most common).
  • Late-onset.

PFK is needed for glycolysis. The enzyme deficiency results in the accumulation of glycogen in the tissues. The enzyme deficiency can also lead to increased uric acid production and therefore possible gout. There may be a compensated haemolytic anaemia.

PFK has muscle, liver and platelet subunits. In muscle tissue, it is only composed of muscle subunits but erythrocyte PFK is composed of both muscle and liver subunits. This means that in classic PFK deficiency, there is no PFK activity in muscle and about 50% activity in erythrocytes.

NEW - log your activity

  • Notes Add notes to any clinical page and create a reflective diary
  • Track Automatically track and log every page you have viewed
  • Print Print and export a summary to use in your appraisal
Click to find out more »
  • It is very rare and has been reported in approximately 100 patients worldwide.[2]
  • Symptoms may be mild in some people so there may be some cases that go unrecognised.
  • Males appear to be affected more commonly than females.
  • It is more common in Ashkenazi Jews.[1]

Infantile-onset form[2] 

  • The cases reported have presented under the age of 1 year.
  • Clinical features can include myopathy, psychomotor impairment, cataracts and joint contractures.
  • Death usually occurs during childhood.
  • There is a 2007 case report of a boy with PFK deficiency who presented, aged 3 days, with neonatal seizures and early infantile non-progressive muscle weakness. He was gaining in his developmental milestones and his seizures were controlled on medication.[3] 

Classic form:[4] 

  • Symptoms are usually first noticed in childhood.
  • There is exercise intolerance with muscle pain, easy muscle fatigue, weakness and stiffness. Symptoms improve with rest.
  • Nausea and vomiting can occur after exercise.
  • If exercise intensity is increased, severe muscle cramps can occur.
  • Myoglobinuria can occur after intense exercise. This can (rarely) lead to acute kidney injury.
  • A compensated haemolysis may also be present and can lead to haemolytic anaemia and sometimes jaundice.
  • Physical examination may be normal.
  • Gallstones (due to raised bilirubin) and gout may be other clinical features.
  • Neurological symptoms have been reported in one case study, including complex partial seizures, diplopia, hyporeflexia, central facial palsy, and upper extremity weakness. The same patient had cardiac involvement (supraventricular tachycardia, thickened mitral valve, mitral valve insufficiency, enlarged left atrium, left ventricular hypertrophy, and diastolic dysfunction).[5] 

Late-onset form

  • This presents in adults as progressive muscle and limb weakness without cramps or myoglobinuria.
  • Blood tests:
    • Serum creatine kinase is usually raised.
    • Fasting glucose: hypoglycaemia.
    • Uric acid: hyperuricaemia.
    • Bilirubin may be elevated; check LFTs (liver failure may occur).
    • FBC can show anaemia with a raised reticulocyte count.
    • Monitor renal function tests if myoglobinuria is present.
  • Urinalysis:
    • There may be myoglobinuria after exercise.
  • Imaging and electrophysiology:
    • Cortical atrophy and ventricular dilatation may be seen on brain imaging in the infantile form.
    • Electromyography (EMG) may show changes consistent with myopathy or may be normal.
  • Muscle biopsy:
    • Assay of PFK in muscle tissue shows reduced levels and can give a definitive diagnosis.
  • No specific treatment exists.
  • The patient (or parents/carers) should be given information about the disorder and advised to avoid high-carbohydrate meals, as they can exacerbate exercise intolerance.
  • A healthy diet should be encouraged. There is evidence that a high-protein diet may improve muscle function and slow progression of the disease.
  • Anaerobic exercise should be avoided.
  • Renal function should be monitored.
  • Genetic counselling should be offered. Prenatal detection may be possible in families with identifiable mutations.
  • Gene therapy may be possible for the future.
  • The few reported cases with the infantile variant have died during early childhood (with the exception of the recent case report which may be a different variant).
  • The other types are usually only relatively mild disorders, and only require minor lifestyle restrictions to avoid complications such as acute kidney injury.

Further reading & references

  1. Glycogen storage disease VII, GSD7; Online Mendelian Inheritance in Man (OMIM)
  2. Toscano A, Musumeci O; Tarui disease and distal glycogenoses: clinical and genetic update. Acta Myol. 2007 Oct;26(2):105-7.
  3. Al-Hassnan ZN, Al Budhaim M, Al-Owain M, et al; Muscle phosphofructokinase deficiency with neonatal seizures and nonprogressive course. J Child Neurol. 2007 Jan;22(1):106-8.
  4. Musumeci O, Bruno C, Mongini T, et al; Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord. 2012 Apr;22(4):325-30. doi: 10.1016/j.nmd.2011.10.022. Epub 2011 Nov 30.
  5. Finsterer J, Stollberger C; Progressive mitral valve thickening and progressive muscle cramps as manifestations of glycogenosis VII (Tarui's Disease). Cardiology. 2008;110(4):238-40. Epub 2007 Dec 12.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Michelle Wright
Current Version:
Peer Reviewer:
Dr Adrian Bonsall
Document ID:
2607 (v24)
Last Checked:
21/08/2014
Next Review:
20/08/2019